What Does EGFR Exon 20 Mean?

EGFR stands for epidermal growth factor receptor. It is a protein that sits on the surface of a cell like an antenna. When a growth signal lands on it, the antenna tells the cell to divide.

EGFR is also the name of the gene that holds the recipe for that antenna. A gene is written in sections. Each coding section is called an exon, and they are numbered in order. Exon 20 is simply the twentieth one.

An exon 20 insertion means extra genetic letters have been slipped into that section. The antenna that gets built is slightly the wrong shape. It sends a grow signal even when no growth factor is present, so the cell keeps dividing.

Your report may print it as EGFR exon 20 insertion, ex20ins, or exon 20 ins. All three mean the same thing.

Most lung cancers with an EGFR change carry one of two well-known types. One is a deletion in exon 19. The other is a single letter swap called L858R. Pills known as EGFR tyrosine kinase inhibitors, or TKIs, work well against those two.

Exon 20 insertions behave differently. An NIH drug reference describes them as often responsible for resistance to conventional EGF receptor inhibitors such as erlotinib and gefitinib, because the extra letters change the shape of the pocket the pill is meant to sit in.

"Exon 20 insertion" is not one thing, though. It covers many different insertions at different points in the exon, and they do not all behave the same way; a few sit closer in behaviour to the common sensitising changes. This is why the exact variant named on your report matters more than the category does.

The National Cancer Institute's treatment summary reflects this split. It lists EGFR TKIs for patients with EGFR variants, then lists a separate line, EGFR-directed therapy for patients with EGFR exon 20 insertions, with amivantamab named under it.

So this is not a worse result or a better one. It points down a different route. Which treatment that route leads to depends on the exact insertion, on the setting — early-stage or advanced, first treatment or later — and on what each drug's current approval covers, so the label wording is the thing to check rather than the category name.

Amivantamab is not a pill. An NIH drug reference calls it a bispecific monoclonal antibody that inhibits the receptors of both epidermal growth factor (EGF) and mesenchymal epithelial transition factor (MET). Bispecific means it grips two targets at once. It is given as a drip into a vein.

The FDA first cleared it on May 21, 2021, under accelerated approval. That first clearance was for people whose disease had progressed on or after platinum-based chemotherapy. In the CHRYSALIS trial, the overall response rate was 40% (95% CI, 29%-51%). Median duration of response was 11.1 months (95% CI, 6.9-not evaluable). Overall response rate means the share of people whose tumors shrank by a set amount.

On March 1, 2024, the FDA granted full approval for first-line use with chemotherapy in locally advanced or metastatic disease.

The measure was progression-free survival, or PFS. That is the time before a scan shows the cancer growing again. Median PFS was 11.4 months (95% CI: 9.8, 13.7) with amivantamab plus chemotherapy. It was 6.7 months (95% CI: 5.6, 7.3) with chemotherapy alone. The hazard ratio was 0.40 (95% CI: 0.30, 0.53; p-value<0.0001).

A median is a midpoint, not a promise. Half the group did better than the figure and half did worse.

Mobocertinib was a pill aimed at the same target. It was granted accelerated approval in 2021. It was withdrawn from use in October 2023 after a phase 3 trial failed to show a significant effect on progression-free survival.

That history is worth knowing for two reasons. Older pages and older printouts may still name it. And it shows what accelerated approval means: an early clearance based on tumor shrinkage, which can be revoked if the confirming trial falls short.

Exon 20 insertions are found by reading the gene, not by looking at cells under a microscope. The National Cancer Institute describes tests that check for many biomarkers at the same time, called multigene tests or panel tests.

The sample can come from tumor tissue taken at biopsy or surgery. It can also come from a blood draw, which the National Cancer Institute notes is useful if you can't safely get a tumor biopsy. Blood tests of this kind look for tumor DNA floating in plasma.

The 2021 approval was paired with a specific blood-based companion diagnostic, Guardant360 CDx. A companion diagnostic is a test the FDA has reviewed alongside a drug to select who should receive it.

The finding names a target. It does not give a stage, a grade, or a prognosis.

It also does not confirm that a drug will work for you. Response rates describe groups. Yours is a single case, and the trial numbers cannot be read as a personal forecast.

A negative report needs care too. If only a narrow test was run, or if a blood sample carried too little tumor DNA, the change could be missed. Ask which test was used and whether the sample was adequate.

Finally, a result on paper is not a plan. Fitness, other health problems, prior treatment, and your own goals all shape what happens next.

• Which exact insertion was found, and where in exon 20 does it sit?
• Was this a tissue test or a blood test, and was the sample adequate?
• Was a broad panel used, or a narrow one that checks only common spots?
• If the result is negative or unclear, would testing on another sample type add anything in my case?
• Is amivantamab an option now, or after another treatment first?
• What side effects should I plan for with an infusion drug?
• Is a clinical trial open for this specific change?

Start with Biomarker Testing, Pathology Reports, Biopsy, and Getting a Second Opinion.

• U.S. Food and Drug Administration — FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications.
• U.S. Food and Drug Administration — FDA grants accelerated approval to amivantamab-vmjw for metastatic non-small cell lung cancer.
• National Cancer Institute — Non-Small Cell Lung Cancer Treatment (PDQ) Health Professional Version.
• National Cancer Institute — Biomarker Testing for Cancer Treatment.
• LiverTox (NIH National Library of Medicine) — Amivantamab.
• LiverTox (NIH National Library of Medicine) — Mobocertinib.